Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib

吉非替尼 表皮生长因子受体 肺癌 癌症研究 酪氨酸激酶 医学 表皮生长因子 酪氨酸激酶抑制剂 突变 生物 癌症 内科学 受体 基因 遗传学
作者
Thomas James Lynch,Daphne W. Bell,Raffaella Sordella,Sarada Gurubhagavatula,Ross A. Okimoto,Brian W. Brannigan,Patricia L. Harris,Sara M. Haserlat,Jeffrey G. Supko,Frank G. Haluska,David N. Louis,David C. Christiani,Jeff Settleman,Daniel A. Haber
出处
期刊:The New England Journal of Medicine [Massachusetts Medical Society]
卷期号:350 (21): 2129-2139 被引量:11555
标识
DOI:10.1056/nejmoa040938
摘要

BACKGROUND: Most patients with non-small-cell lung cancer have no response to the tyrosine kinase inhibitor gefitinib, which targets the epidermal growth factor receptor (EGFR). However, about 10 percent of patients have a rapid and often dramatic clinical response. The molecular mechanisms underlying sensitivity to gefitinib are unknown. METHODS: We searched for mutations in the EGFR gene in primary tumors from patients with non-small-cell lung cancer who had a response to gefitinib, those who did not have a response, and those who had not been exposed to gefitinib. The functional consequences of identified mutations were evaluated after the mutant proteins were expressed in cultured cells. RESULTS: Somatic mutations were identified in the tyrosine kinase domain of the EGFR gene in eight of nine patients with gefitinib-responsive lung cancer, as compared with none of the seven patients with no response (P<0.001). Mutations were either small, in-frame deletions or amino acid substitutions clustered around the ATP-binding pocket of the tyrosine kinase domain. Similar mutations were detected in tumors from 2 of 25 patients with primary non-small-cell lung cancer who had not been exposed to gefitinib (8 percent). All mutations were heterozygous, and identical mutations were observed in multiple patients, suggesting an additive specific gain of function. In vitro, EGFR mutants demonstrated enhanced tyrosine kinase activity in response to epidermal growth factor and increased sensitivity to inhibition by gefitinib. CONCLUSIONS: A subgroup of patients with non-small-cell lung cancer have specific mutations in the EGFR gene, which correlate with clinical responsiveness to the tyrosine kinase inhibitor gefitinib. These mutations lead to increased growth factor signaling and confer susceptibility to the inhibitor. Screening for such mutations in lung cancers may identify patients who will have a response to gefitinib.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
希望天下0贩的0的应助被溧谦采纳,获得10
刚刚
Zhu发布了新的文献求助10
刚刚
Hello的应助被愤怒的迎南采纳,获得10
刚刚
清秀豪英完成签到,获得积分10
1秒前
石宇航发布了新的文献求助10
1秒前
鸭梨发布了新的文献求助10
1秒前
深情安青的应助被鬼舞采纳,获得10
1秒前
cdercder的应助被风里等你采纳,获得10
1秒前
脑洞疼的应助被黑色的星星采纳,获得10
2秒前
大橘发布了新的文献求助10
2秒前
2秒前
2秒前
2秒前
2秒前
怕黑汽车完成签到 ,获得积分10
3秒前
水弘的应助被稳重的馒头采纳,获得10
3秒前
小马甲的应助被w17638619025采纳,获得10
4秒前
4秒前
头头猫完成签到 ,获得积分10
4秒前
LIYUZHEN完成签到,获得积分10
4秒前
安妮LAZY完成签到,获得积分10
4秒前
4秒前
Bear完成签到 ,获得积分10
4秒前
清秀豪英发布了新的文献求助10
5秒前
5秒前
好学的猪完成签到,获得积分10
5秒前
英姑的应助被tlc_191026采纳,获得30
5秒前
粗犷的冬寒完成签到,获得积分10
6秒前
田12发布了新的文献求助10
6秒前
7秒前
华仔的应助被奋斗忆南采纳,获得10
8秒前
wjp发布了新的文献求助10
8秒前
橙子发布了新的文献求助10
8秒前
852的应助被清爽的绿蓉采纳,获得10
8秒前
ku发布了新的文献求助10
9秒前
huangshizhi完成签到,获得积分10
9秒前
9秒前
科研通AI65的应助被小y同学采纳,获得10
10秒前
彭于晏的应助被小y同学采纳,获得10
10秒前
wanci的应助被kxn采纳,获得10
11秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
Improving the wear resistance of vehicle gear oil by oil soluble LaF3 nanoparticles and typical additives of gear oil 500
Boundaries and Bodhisattvas 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8183508
求助须知:如何正确求助?哪些是违规求助? 9572862
关于积分的说明 21827639
捐赠科研通 7780681
什么是DOI,文献DOI怎么找? 3434016
关于科研通互助平台的介绍 2558189
邀请新用户注册赠送积分活动 2480405